# Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

> **NCT03680131** · PHASE2 · COMPLETED · sponsor: **Edesa Biotech Inc.** · enrollment: 211 (actual)

## Conditions studied

- Allergic Contact Dermatitis

## Interventions

- **DRUG:** EB01 Cream Placebo
- **DRUG:** EB01 Cream 0.2%
- **DRUG:** EB01 Cream 1.0%
- **DRUG:** EB01 Cream 2.0%

## Key facts

- **NCT ID:** NCT03680131
- **Lead sponsor:** Edesa Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-15
- **Primary completion:** 2022-09-21
- **Final completion:** 2023-01-17
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680131, "Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03680131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*